Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (5687)	11/20/1998 5:13:00 PM
From: Joe E.	Respond to of 6136

margie- Thanks for the background on IL-2. Seems like the kind of drug one could give to a person with metastatic cancer, but it would be hard to give it to a person with a stable HIV infection conrolled by HAART.

To: margie who wrote (5687)	11/20/1998 6:53:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

>> There is no controversy about the side effects of IL-2. Apparently there are less side effects wih IL-2 if administered subcutaneously, than through IV. << I was collaborating with BioTherapeutics (now belly up) of Franklin/Memphis when the first patients were receiving Chiron's IL-2 there. Dosing was iv and experimental. I got to talk to one of the early "success story" patients who had a huge renal Ca that went undetectable. He was enthusiastic, but described a nightmare of side effects that terminated with a skin peel. Not fun...... brave patients.